TY - JOUR
T1 - Pharmacokinetic analysis of cefozopran in neonatal infections
T2 - Population pharmacokinetics using nonmem
AU - Sakurai, Yuichi
AU - Hishikawa, Tamotsu
AU - Hiramatsu, Nobuyoshi
AU - Sagara, Yasuhito
AU - Kuwahara, Masaaki
AU - Nagasaki, Masaru
AU - Hujimaki, Tomoko
AU - Fuji, Ryochi
PY - 1999/1
Y1 - 1999/1
N2 - This report describes the results on pharmacokinetics, efficacy and safety of cefozopran (CZOP) in neonatal patients. Enrolled patients were 136 in total whose informed consents to enter this study had been given by their parents. Among them, blood samples were collected from 42 neonates to analyze concentrations of CZOP by population pharmacokinetics (PPK) methods. Based on this analysis, the average pharmacokinetic parameters of CZOP and the variabilities of them in different morbid pharmacological backgrounds and in different subjects were evaluated. This PPK analysis showed that clearance (CL) and distribution volume (Vd) of CZOP could be estimated by the following equations; CL=0.0452XWT 1.75 (in the case of the postnatal age of over than 1 day) CL=0.623X0.0452WT 1.765 (in the case of the postnatal age of 1 day or less) Vd = 0.455XWT where WT indicates body weight in kg. The coefficients of variation among individual subjects on CL and Vd were found to he 20.7% and 20.0%, respectively. From this PPK analysis it was indicated that the elimination of CZOP is dependent on the postnatal age and is approximately 38% lower in the younger group than in the older group. Therefore, it could be concluded that, though the cases of evaluation were small in number, adjustment of dosing of CZOP is necessary, particularly in prolongation of intervals of administration, in cases of postnatal age of 1 day or less.
AB - This report describes the results on pharmacokinetics, efficacy and safety of cefozopran (CZOP) in neonatal patients. Enrolled patients were 136 in total whose informed consents to enter this study had been given by their parents. Among them, blood samples were collected from 42 neonates to analyze concentrations of CZOP by population pharmacokinetics (PPK) methods. Based on this analysis, the average pharmacokinetic parameters of CZOP and the variabilities of them in different morbid pharmacological backgrounds and in different subjects were evaluated. This PPK analysis showed that clearance (CL) and distribution volume (Vd) of CZOP could be estimated by the following equations; CL=0.0452XWT 1.75 (in the case of the postnatal age of over than 1 day) CL=0.623X0.0452WT 1.765 (in the case of the postnatal age of 1 day or less) Vd = 0.455XWT where WT indicates body weight in kg. The coefficients of variation among individual subjects on CL and Vd were found to he 20.7% and 20.0%, respectively. From this PPK analysis it was indicated that the elimination of CZOP is dependent on the postnatal age and is approximately 38% lower in the younger group than in the older group. Therefore, it could be concluded that, though the cases of evaluation were small in number, adjustment of dosing of CZOP is necessary, particularly in prolongation of intervals of administration, in cases of postnatal age of 1 day or less.
UR - http://www.scopus.com/inward/record.url?scp=0033038977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033038977&partnerID=8YFLogxK
M3 - Article
C2 - 10202684
AN - SCOPUS:0033038977
SN - 0368-2781
VL - 52
SP - 16
EP - 23
JO - Japanese Journal of Antibiotics
JF - Japanese Journal of Antibiotics
IS - 1
ER -
